Myocardial infarction · patients with suspected or diagnosed myocardial infarction
Beta‐blockers showed no clear difference in myocardial infarction at maximum compared with placebo or no intervention (low certainty).
2 findings from 1 review
Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality maximum · patients with suspected or diagnosed myocardial infarction
Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · heart failure associated with central sleep apnoea
It is very uncertain whether PAP therapy changes all‐cause mortality compared with usual care (very low certainty).
1 finding from 1 review
Cardiac disease‐ related mortality · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related mortality compared with usual care (moderate certainty).
1 finding from 1 review
Patient readmissions · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in all‐cause rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
Cardiac‐related rehospitalisation · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
QoL · heart failure associated with central sleep apnoea
2 findings from 1 review
Adverse events · heart failure associated with central sleep apnoea
1 finding from 1 review
Cardiovascular mortality · patients without heart failure
Natriuretic peptide‐guided treatment showed no clear difference in cardiovascular mortality compared with standard care (low certainty).
1 finding from 1 review
Cardiovascular hospitalisation (as defined by trialists) · patients without heart failure
Natriuretic peptide‐guided treatment probably leads to lower cardiovascular hospitalisation (as defined by trialists) compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients without heart failure
Natriuretic peptide‐guided treatment showed no clear difference in all‐cause mortality compared with standard care (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · patients without heart failure
Natriuretic peptide‐guided treatment probably leads to lower all‐cause hospitalisation (all occurrences) compared with standard care (moderate certainty).
1 finding from 1 review
Ventricular dysfunction (as defined by trialists) · patients without heart failure
Natriuretic peptide‐guided treatment leads to lower ventricular dysfunction (as defined by trialists) compared with standard care (high certainty).
1 finding from 1 review
Change in NP level at the end of · patients without heart failure
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review